Hypertensive nephropathy: Prevention and treatment recommendations

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 16, 2010, Pages 2675-2686

  Hart, Peter D ^a   Bakris, George L ^b  

^a Division of Medical Toxicology   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Albuminuria; Chronic kidney disease; Hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOOP DIURETIC AGENT; LOSARTAN; METOLAZONE; PLACEBO; SODIUM; SPIRONOLACTONE; VERAPAMIL;

3' UNTRANSLATED REGION; AFRICAN AMERICAN; ALDOSTERONE RELEASE; ARTERIAL STIFFNESS; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CLINICAL STUDY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DIURESIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; FOLLOW UP; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HIGH POTASSIUM INTAKE; HIGH RISK PATIENT; HIGH SODIUM INTAKE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTENSIVE NEPHROPATHY; HYPOKALEMIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ABSORPTION; MICROALBUMINURIA; MONOTHERAPY; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; POST HOC ANALYSIS; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SODIUM EXCRETION; SODIUM RESTRICTION; SYMPATHETIC NERVE; TREATMENT INDICATION; VASOCONSTRICTION; VASODILATATION; WEIGHT REDUCTION;

ALBUMINURIA; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 78049386420     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.485612     Document Type: Review

References (90)

1. Available from: www.usrds.org/2009/pdf vol.3
2. Fervanca FC, Textor SC, Rosenthal D. Nephrosclerosis. Available from: http://edmedicine.medscape.com [Last accessed 23 March 2010]
3. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-8
4. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
5. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72
6. Chua DC, Bakris GL. Is proteinuria a plausible target of therapy? Curr Hypertens Rep 2004;6:177-81
7. Culleton BF, Larson MG, Parfrey PS, et al. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med 2000;109:1-8
8. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305
9. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 2003;42:1050-65
10. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S1-290
11. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004;43:699-706
12. Brod J, Bahlmann J, Cachovan M, et al. Mechanisms for the elevation of blood pressure in human renal disease. Preliminary report. Hypertension 1982;4:839-44
13. Bidani AK, Hacioglu R, Abu-Amarah I, et al. 'Step' vs. 'dynamic' autoregulation: implications for susceptibility to hypertensive injury. Am J Physiol Renal Physiol 2003;285:F113-20
14. Grisk O, Rettig R Interactions between the sympathetic nervous system and the kidneys in arterial hypertension. Cardiovasc Res 2004;61:238-46
15. Garg JP, Ellis R, Elliott WJ, et al. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. Am J Nephrol 2005;25:393-9
16. Safar M, Chamiot-Clerc P, Dagher G, Renaud JF. Pulse pressure, endothelium function, and arterial stiffness in spontaneously hypertensive rats. Hypertension 2001;38:1416-21
17. Safar M, Laurent S, Safavian A, et al. Sodium and large arteries in hypertension. Effects of indapamide. Am J Med 1988;84:15-9
18. Freedman BI, Sedor JR. Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008;19:2047-51
19. Freedman BI, Hicks PJ, Bostrom MA, et al. Polymorphism in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end stage renal disease historically attributed to hypertension in African American. Kidney Int 2009;75:736-45
20. Freedman BI, Kopp JB, Winkler CA, et al. Polymorphism in the non-muscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study. Am J Nephrol 2009;26:626-32
21. Salem RM, Cadman PE, Chen Y, et al. Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol 2008;19:600-14
22. Chen Y, Rao F, Rodriguez-Flores JL, et al. Naturally occurring human genetic variation in the 3'-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion. J Am Coll Cardiol 2008;52:1468-81
23. Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. Clin Lab Med 2006;26:635-53, vi
24. Bakris GL. Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep 2004;6:352-6
25. Giner V, Tormos C, Chaves FJ, et al. Microalbuminuria and oxidative stress in essential hypertension. J Intern Med 2004;255:588-94
26. Kistorp C, Raymond I, Pedersen F, et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005;293:1609-16
27. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003;16:952-8
28. Steinke JM, Sinaiko AR, Kramer MS, et al. The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005;54:2164-71
29. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005;45:198-202 (Pubitemid 40179960)
30. Bakris GL, Fonseca V, Katholi RE, et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005;46:1309-15
31. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003;42:617-22
32. Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int 2006;70:1214-22
33. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:281-7
34. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-20
35. Lea J, Greene T, Hebert L, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005;165:947-53
36. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-64
37. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51
38. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61
39. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007;49:12-26
40. Toto RD. Proteinuria reduction: mandatory consideration or option when selecting an antihypertensive agent? Curr Hypertens Rep 2005;7:374-8
41. Khosla N, Kalaitidis R, Bakris GL. The kidney, hypertemsion and remaining challenges. Med Clin N Am 2009;93:697-715
42. Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005;16:2170-9 Documents the association between lowering arterial blood pressure and cardiovascular events.
43. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005;142:342-51
44. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31
45. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365:939-46
46. Appel LJ, Wright JT Jr, Greene T, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008;168:832-9
47. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244-52
48. Mishra SI, Jones-Burton C, Fink JC, et al. Does dietary salt increase the risk for progression of kidney disease? Curr Hypertens Rep 2005;7:385-91
49. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10
50. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62
51. Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 1998;352:1252-6
52. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:936-46
53. Bakris GL, Weir MR Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93
54. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
55. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
56. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
57. Mann JF, Schmieder RE, McQueeen M, et al. Renal outcomes with Telmisartan, ramipril, or both, in people at high risk (the ONTARGET study): a multicentre, randomized, double blind, controlled trial. Lancet 2008;372:547-53
58. Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol 2004;24:168-75
59. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev 2008;(4):CD007066
60. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46
61. Parving HH, Brenner BM, McMurrayJJ, et al. Aliskiren Trial in Type 2 Diabetes using cardio-renal endpoints: rationale and study design. Nephrol Dial Transplant 2009;24:1663-71
62. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-45
63. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008;51:199-211
64. Lewis EJ, Hunsicker LG, Clarke WR, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
65. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92
66. Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich) 2005;7:354-6
67. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9
68. Eriksson JW, Jansson PA, Carlberg B, et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension 2008;52:1030-7
69. Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48:219-24
70. Bakris G, Molitch M, Zhou Q, et al. Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometab Syndr 2008;3:18-25
71. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;29:2592-7
72. Bakris G, Stockert J, Molitch M, et al. Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab 2009;11:177-87
73. Kim GH. Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am J Nephrol 2004;24:595-605
74. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-23
75. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Eng J Med 2008;359:2417-28
76. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81
77. Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004;65:1991-2002
78. Toto RD. Management of hypertensive chronic kidney disease: role of calcium channel blockers. J Clin Hypertens (Greenwich) 2005;7:15-20
79. Boero R, Rollino C, Massara C, et al. Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial. J Nephrol 2001;14:15-8
80. Nathan S, Pepine CJ, Bakris GL. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension 2005;46:637-42
81. Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-50
82. Bakris GL, Mangrum A, Copley JB, et al. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997;29:744-50
83. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163:1555-65
84. Kalaitzidis R, Bakris G. Should nephrologists use beta-blockers? A perspective. Nephrol Dial Transplant 2009;24:701-2
85. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53
86. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227-36
87. Kumar KV, Shifow AA, Naidu MU, Ratnakar KS. Carvedilol: a beta blocker with antioxidant property protects against gentamicin-induced nephrotoxicity in rats. Life Sci 2000;66:2603-11
88. Singh D, Chander V, Chopra K. Carvedilol, an antihypertensive drug with antioxidant properties, protects against glycerol-induced acute renal failure. Am J Nephrol 2003;23:415-21
89. Rachmani R, Levi Z, Slavachevsky I, et al. Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. Nephron 1998;80:175-82
90. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003;42:239-46